Country: Canada
Language: English
Source: Health Canada
LAROTRECTINIB (LAROTRECTINIB SULFATE)
BAYER INC
L01EX12
LAROTRECTINIB
100MG
CAPSULE
LAROTRECTINIB (LAROTRECTINIB SULFATE) 100MG
ORAL
15G/50G
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0161630002; AHFS:
APPROVED
2019-07-10
_VITRAKVI_ _(larotrectinib) Product Monograph_ Page 1 of 37 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR VITRAKVI ® larotrectinib capsules 25 mg and 100 mg larotrectinib (as larotrectinib sulfate) larotrectinib oral solution 20 mg/mL larotrectinib (as larotrectinib sulfate) Antineoplastic Agent (ATC: L01XE53) _VITRAKVI, indicated for:_ _ _ _ - the treatment of adult and pediatric patients with solid tumours that: _ • _have a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion without a known _ _acquired resistance mutation, _ • _are metastatic or where surgical resection is likely to result in severe morbidity, and _ • _have no satisfactory treatment options _ _has been issued marketing authorization with conditions, pending the results of trials to verify _ _its clinical benefit. Patients should be advised of the nature of the authorization. For further _ _information for VITRAKVI please refer to Health Canada’s Notice of Compliance with _ _conditions - drug products web site: https://www.canada.ca/en/health-canada/services/drugs-_ _health-products/drug-products/notice-compliance/conditions.html. _ Bayer Inc. 2920 Matheson Blvd East, Mississauga, Ontario L4W 5R6 www.bayer.ca Date of Initial Authorization: July 4, 2019 Date of Revision: August 17, 2023 Submission Control No: 274854 © 2023, Bayer Inc. ® TM see www.bayer.ca/tm-mc _VITRAKVI_ _(larotrectinib) Product Monograph_ Page 2 of 37 WHAT IS A NOTICE OF COMPLIANCE WITH CONDITIONS (NOC/C)? _An NOC/c is a form of market approval granted to a product on the basis of PROMISING _ _evidence of clinical effectiveness following review of the submission by Health Canada. _ _Products authorized under Health Canada’s NOC/c policy are intended for the treatment, _ _prevention or diagnosis of a serious, life-threatening or severely debilitating illness. They _ _have demonstrated promising benefit, are of high quality and possess an acceptable _ _safety profile based on a benefit/risk assessment. In addition, they either respond to a _ _se Read the complete document